Fatty liver has become one of the most common metabolic liver problems in the United States, and many people do not know they have it.

Under the newer terminology now used more often, what was previously called NAFLD (non-alcoholic fatty liver disease) is increasingly referred to as MASLD (metabolic dysfunction-associated steatotic liver disease).

Estimates of prevalence among U.S. adults vary by diagnostic definition. NHANES-based studies have reported estimates of roughly 32%–42% for MASLD or related steatotic liver disease, depending on the survey period, imaging threshold and definition used. See the NHANES 2017–2023 study and the NHANES 2017–2020 study for examples of how those estimates differ.

Retatrutide is currently one of the most closely watched investigational drugs in this research area.

The liver-fat findings from its Phase 2a substudy were more than a small change in a single metabolic marker. This article discusses published research findings only. The study-arm amounts described below are not product-selection, dosing, injection, reconstitution, treatment or human-use instructions.

Quick takeaways

  • MASLD is strongly associated with obesity, visceral fat, insulin resistance and abnormal lipid metabolism;
  • Retatrutide is a triple receptor agonist that activates the GIP, GLP-1 and glucagon receptors;
  • A prespecified Phase 2a substudy included 98 participants with MASLD and baseline liver fat of at least 10%;
  • At 48 weeks, the 8 mg research group had a mean relative liver-fat reduction of 81.7%;
  • The 12 mg research group had a mean relative liver-fat reduction of 86.0%;
  • At 48 weeks, 89% and 93% of evaluable participants in the 8 mg and 12 mg research groups, respectively, reached liver fat below 5%, the study's defined normal range;
  • Most of the liver-fat reduction occurred during the first 24 weeks;
  • Liver-fat improvement was correlated with weight loss, reductions in waist or abdominal fat, and changes in insulin-sensitivity and lipid-metabolism markers.

These figures come from the Nature Medicine Phase 2a MASLD study. They are not Selection Peptide Lab testing results and should not be interpreted as an expected effect of a catalog material.

What is MASLD?

MASLD involves abnormal fat accumulation in the liver together with one or more cardiometabolic risk factors.

It commonly appears alongside:

  • Insulin resistance;
  • Obesity;
  • Excess abdominal or visceral fat;
  • Abnormal blood glucose;
  • Elevated triglycerides;
  • High blood pressure;
  • Other features of metabolic syndrome.

Fatty liver is therefore not always an isolated liver issue. It can be one expression of broader energy-metabolism disruption.

Early MASLD may cause few noticeable symptoms. Many people discover it only after imaging, blood testing or an examination for another reason identifies liver-fat accumulation.

Some people may remain at the stage of simple steatosis, while others may progress to inflammation, MASH and fibrosis, which can increase the risk of serious liver disease. MASLD is also closely associated with type 2 diabetes and cardiovascular risk.

What did the Retatrutide Phase 2a liver study find?

This was not a separate large liver-disease trial. It was a prespecified imaging substudy within a Phase 2 obesity trial of Retatrutide.

Researchers selected 98 participants with MASLD and at least 10% liver fat measured by MRI-PDFF from the main study. Participants were randomized to placebo or Retatrutide research groups of 1 mg, 4 mg, 8 mg or 12 mg. These amounts describe the clinical-trial arms only; they are not a prescription, product-selection or human-use recommendation.

The main question was:

How much can Retatrutide reduce the amount of fat in the liver under this study design?

The results were substantial, but they need to be read together with the study population, imaging method and follow-up limitations.

At 24 weeks

The reported mean relative change in liver fat from baseline was:

  • 1 mg: −42.9%
  • 4 mg: −57.0%
  • 8 mg: −81.4%
  • 12 mg: −82.4%
  • Placebo: +0.3%

The Nature Medicine paper reported that all Retatrutide research groups were statistically different from placebo at week 24. In other words, much of the measured effect had already appeared during the first six months.

At 48 weeks, the highest research group reached an 86% liver-fat reduction

At 48 weeks, the paper reported the following mean relative changes in liver fat from baseline:

  • 1 mg: −51.3%
  • 4 mg: −59.0%
  • 8 mg: −81.7%
  • 12 mg: −86.0%
  • Placebo: −4.6%

The most accurate way to describe the result is:

In this Phase 2a MASLD substudy, the 8 mg and 12 mg Retatrutide research groups had mean relative liver-fat reductions of approximately 82% and 86%, respectively, at 48 weeks.

It is less accurate to say:

“Retatrutide reduced NAFLD by 81%–86%.”

The first wording describes a measured relative change in liver fat. The second can make readers think that disease incidence fell by 86% or that 86% of participants were cured.

A more understandable endpoint: liver fat below the study's normal-range threshold

The study also examined whether total liver fat fell below 5%. The paper used liver fat below 5% as its study-defined normal range.

At week 24:

  • 8 mg research group: 79%;
  • 12 mg research group: 86%.

Reached liver fat below 5%.

At week 48:

  • 8 mg research group: 89%;
  • 12 mg research group: 93%.

Reached the same study endpoint. These percentages refer to participants with evaluable MRI liver-fat data in the relevant groups, not to every person initially randomized.

The result means that among participants following the relevant research protocol who had 48-week MRI data, most participants in the higher research groups had liver fat below the study-defined threshold.

There is an important limitation. Fewer participants had usable MRI liver-fat data at week 48 than at week 24. The original paper's figure caption reports 48-week MRI liver-fat data for 8 placebo participants, 9 participants in the 1 mg group, 9 in the 4 mg group, 8 in the 8 mg group and 9 in the 12 mg group. The 93% figure is notable, but it should not be promoted outside the context of this small evaluable sample.

Why might Retatrutide have such a marked effect on liver fat?

Retatrutide is different from a single-receptor approach. The paper describes it as a triple receptor agonist that activates GIP, GLP-1 and glucagon receptors.

GLP-1 receptor

GLP-1 receptor signaling is studied in relation to appetite, satiety and glucose regulation.

GIP receptor

GIP receptor signaling is involved in research on nutrient signaling, insulin secretion, adipose tissue and energy metabolism.

Glucagon receptor

Glucagon receptor signaling may contribute to energy expenditure, fat oxidation and substrate use. These are research mechanisms and do not directly establish the effect, quality or suitability of any online product.

The research hypothesis is therefore broader than “eat less.” It examines several layers of energy intake, energy expenditure and substrate handling at the same time.

Why would the liver lose fat as overall metabolism changes?

Liver fat does not appear in isolation. Long-term energy surplus and insulin resistance can change fatty-acid flow: more fat can reach the liver, while the liver may also produce more fat itself.

When fat input and synthesis remain greater than oxidation and export, fat can accumulate in the liver.

In this study, liver-fat reduction was correlated with weight loss, waist reduction, abdominal-fat changes, and changes in insulin-sensitivity and lipid-metabolism markers. A more cautious interpretation is not that “Retatrutide specifically removes fat from the liver,” but that:

A changed metabolic environment may reduce the liver's previous fat and energy burden.

Correlation does not prove that one mechanism caused all of the liver-fat change. It also does not establish that every related product would produce the same result.

Has Retatrutide proven that it can treat MASH or reverse liver fibrosis?

No. This distinction is essential.

The clearest finding from this study is that MRI measured a substantial reduction in liver fat.

That is an important signal, but it does not prove:

  • Reversal of liver fibrosis;
  • Complete resolution of MASH;
  • Elimination of cirrhosis risk;
  • A reduction in long-term liver failure risk.

The original paper reported changes in some MASH- or fibrosis-related biomarkers, but ALT, AST, FIB-4 and ELF did not show a consistent placebo-adjusted improvement. The authors also described the Phase 2 substudy as hypothesis-generating rather than definitive.

The most accurate conclusion is therefore:

Retatrutide showed a strong liver-fat-lowering signal in participants with MASLD, but larger and longer studies are still needed to determine effects on hard clinical liver outcomes.

Larger follow-up research is underway

This is why larger Retatrutide liver studies are important.

The SYNERGY-OUTCOMES ClinicalTrials.gov record describes a Phase 3 study expected to enroll approximately 4,500 adults with high-risk MASLD. It compares Retatrutide, Tirzepatide and placebo and focuses on major adverse liver outcomes, not only MRI-measured liver fat. The record describes a substantially longer follow-up period than 48 weeks.

That next step matters.

Phase 2a tells us:

“Liver fat can fall substantially under this study design.”

The larger study needs to answer:

“Can that liver-fat reduction ultimately reduce serious liver events?”

The broader significance

The most important feature of Retatrutide research may not be one weight-loss number in isolation.

In the main Phase 2 obesity trial, the 12 mg research group had a mean weight reduction of 24.2% at 48 weeks; see the original NEJM Retatrutide Phase 2 trial. The MASLD substudy also observed:

  • Reduced visceral and abdominal fat;
  • Up to an 86% mean relative liver-fat reduction in the highest research group;
  • Most evaluable participants in the higher research groups reaching liver fat below 5%;
  • Concurrent changes in insulin-sensitivity and lipid-metabolism markers.

Together, these findings suggest that obesity, visceral fat, insulin resistance and fatty liver are not always four independent problems. They can be different expressions of the same broader energy-metabolism imbalance.

The research significance of Retatrutide is that it may affect this system through multiple receptor pathways. “May” remains a research hypothesis, not a guarantee about a research material or a human outcome.

Final conclusion

The Retatrutide Phase 2a MASLD data are striking, but the headline numbers should be described precisely.

Not:

“NAFLD decreased by 81%–86% within 48 weeks.”

More accurately:

“In a Phase 2a MASLD substudy, the 8 mg and 12 mg Retatrutide research groups had mean relative liver-fat reductions of 81.7% and 86.0%, respectively, at 48 weeks. Among participants with corresponding evaluable MRI data, 89% and 93% reached liver fat below 5%, the study-defined normal-range threshold.”

That wording is more accurate and, in practice, more credible.

Retatrutide remains investigational. These findings do not prove that it cures MASLD or MASH, reverses advanced liver disease or reduces long-term liver events. They must not be used as medication, dosing, injection, preparation or treatment advice.

Research sources

*For research and educational purposes only. This article is not medical advice and does not provide human-use guidance.*